UroGen Pharma (URGN) Revenue Growth (1y) (2018 - 2026)
Powered by 
Analysis
UroGen Pharma (URGN) Revenue Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 16.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 296.11% |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 199.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 199.22% |
| Mar 31, 2026 | 151.60% |
| Dec 31, 2025 | 54.03% |
| Sep 30, 2025 | 9.04% |
| Jun 30, 2025 | 10.83% |
| Mar 31, 2025 | 7.84% |
| Dec 31, 2024 | 4.40% |
| Sep 30, 2024 | 20.87% |
| Jun 30, 2024 | 3.35% |
| Mar 31, 2024 | 9.24% |
| Dec 31, 2023 | 30.06% |
| Sep 30, 2023 | 29.54% |
| Jun 30, 2023 | 27.31% |
| Mar 31, 2023 | 26.75% |
| Dec 31, 2022 | 11.86% |
| Sep 30, 2022 | 41.81% |
| Jun 30, 2022 | 27.41% |
| Mar 31, 2022 | 81.22% |
| Dec 31, 2021 | 103.04% |
| Sep 30, 2021 | 227.97% |